Glenmark Pharmaceutical launches the biosimilar of Adalimumab in India

Launched under the brand name ADALY, the biosimilar is indicated for the treatment of Plaque Psoriasis and Rheumatoid Arthritis

Mumbai, India; January 04, 2018: Glenmark Pharmaceuticals Limited is pleased to announce the launch of the biosimilar of Adalimumab under a licensing agreement with Cadila Healthcare Ltd., the Zydus group for the treatment of Plaque Psoriasis and Rheumatoid Arthritis. Developed by the researchers at the Zydus Research Centre, the biosimilar of Adalimumab was first launched by Zydus in 2014 and is manufactured at Zydus Biologics, the dedicated facility for product development and manufacturing of biologics and monoclonal antibodies.

The biosimilar will be marketed by Glenmark under the brand name ADALY. Globally, Adalimumab is the number one selling pharmaceutical product. ADALY (Adalimumab) is a TNF inhibiting, anti-inflammatory biologic that binds to tumor necrosis factor (TNFalpha) and reduces inflammatory response.

Glenmark is a leader in dermatology in India and has been at the forefront of introducing new molecules to meet various unmet needs of patients. Recently the company introduced Aprezo (Apremilast) for psoriasis. The launch of ADALY marks the launch of Glenmark’s first biosimilar in Dermatology. Biologics are gaining importance in managing various diseases and Glenmark has a strong focus on developing its own novel biologics. The launch of ADALY is a step towards building a presence in this area. With ADALY, Glenmark will also serve the rheumatoid arthritis patient population.

“Being leaders in the dermatology segment in India, ADALY is an important launch. The launch of this biosimilar will significantly enhance our presence in this segment. We are encouraged by the recent launch of Apremilast for psoriasis in India and the launch of ADALY reaffirms our commitment towards meeting unmet needs of patients and providing the latest treatment options. ADALY will be available to patients in India at a fraction of the global cost”, says Sujesh Vasudevan, President – India Formulations, Middle East and Africa at Glenmark.
About Glenmark Pharmaceuticals Ltd:
Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical organization. It is ranked among the top 75 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2017). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBES (new biological entity). Glenmark has several molecules in various stages of clinical development and is focused in the areas of oncology, dermatology and respiratory.

The company has a significant presence in the branded generics markets across emerging economies including India. Glenmark has 16 manufacturing facilities across five countries and has six R&D centers. The Generics business of Glenmark services the requirements of the US and Western European markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India.

For further information, please contact:
Ramkumar Uppara / Shibani Shah
Glenmark, Mumbai, India
Tel: +91 98201 77907 / +91 22 40189348
Email: corpcomm@glenmarkpharma.com